Managing IP is part of the Delinian Group, Delinian Limited, 8 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2023

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

China patents: How will China’s government reform affect IP in the country?

China announced a huge government reshuffle programme. The sweeping government restructuring programme was said to be the largest reform since the end of the Mao Zedong era in the 1970s. The number of ministerial-level bodies was reduced significantly. The entire structure reflects the aim of streamlining governance, in key areas such as environmental protection, taxation, financial regulations and the legislature system on the administrative side.

In the intellectual property world, the most relevant change is the establishment of a super State Market Regulatory Administration (SMRA). This combines the State Administration for Industry and Commerce (SAIC), the General Administration of Quality Supervision, Inspection and Quarantine (AQSIQ) and the China Food and Drug Administration (CFDA). The antitrust divisions of the National Development and Reform Commission (NDRC) and Ministry of Commerce (MOFCOM) will also be merged into this super ministry. The patent and trade mark offices will be combined and housed under one roof - the SMRA. The responsibilities of the State Intellectual Property Office (SIPO), the State Administration for Industry and Commerce (SAIC) and the General Administration of Quality Supervision, Inspection and Quarantine (AQSIQ) – for patents, trade marks and geographical indications respectively – will all be governed under the SMRA.

Placing the patent and trade mark offices under the new mega ministry SMRA is something that has been discussed before, but the extent of this new authority's powers comes as a surprise. With regard to how it will affect the capabilities of the patent and trade mark functions, it seems the change might be more administrative in nature and cause no major disruptions. It is not necessary that the reorganisation will impact either office negatively, as it will still be the same group of people working at both offices. Both offices should function in the same way as they have done previously.

The restructuring also raises bigger picture questions such as who will now guide the overall direction of IP policy in China and whether there will be a redistribution of resources. Traditionally, the SIPO has been deeply involved in nurturing IP innovation policy and shaping the law, and it reports directly to the State Council, the highest level of authority in the country. SIPO plays an instrumental role in the new patent law amendments and inventor remuneration regulations. Now, any policies to be initiated by SIPO will be checked first by the new SMRA and, if approved, forwarded to the new Ministry of Justice, which is reinvigorated by including the former State Council Legislative Affairs Office. It is believed that before long the SMRA will dictate patent-related policies.

Regarding the SMRA, what is mostly notable is its new leader. Bi Jingquan, former head of the CFDA was just appointed to lead the new regulatory body as party secretary general, together with Mr Zhang Mao, former head of the SAIC, as minister of the SMRA. Bi Jingquan is widely regarded as a hands-on pro-reform and pro-innovation leader who has, for example, been playing a critical role in introducing the pharmaceutical patent linkage system in China. The reform he led in the pharmaceutical area is unprecedented and is clearly part of the foundation for his promotion. He might continue instigating reforms at this new ministry. The progress he will initiate in the area of patent linkage, regulatory data protection and patent term extension will be signals of future reforms in the IP field.

The impact of the consolidation at the central government level remains to be seen at the local level. In fact, in recent years local SMRAs have been established in many cities, starting from Shenzhen. Patent administrative enforcement has already been tried out at some of the local SMRAs. The consolidation of the enforcement powers in both the trade mark and patent area might arguably increase effectiveness and deterrence. What is also notable is the consolidation of the antitrust departments in the SMRA, as it may have some impact on IP-related antitrust regulations. The NDRC and SAIC arguably both have jurisdiction over IP-related antitrust issues. The consolidation, which aims to achieve uniform antitrust law enforcement will probably put an end to this dual jurisdiction.


He Jing

Chen Zhixing

AnJie Law Firm26/F, Tower D, Central International Trade Center6A Jianguomenwai Avenue, Chaoyang District, Beijing 100022, PR ChinaTel: +86 10 8567 5988Fax: +86 10 8567

more from across site and ros bottom lb

More from across our site

IP counsel urge the government to restrict safe harbour exceptions available to intermediaries and clear up doubts with the existing law
A New York lawyer could face sanctions after citing fake judgments generated by ChatGPT, but that doesn’t mean practitioners should shy away from AI
Klaus Grabinski told delegates at a UPC inauguration event that the proposed SEP regulation would limit access to justice
We provide a rundown of Managing IP’s news and analysis coverage from the week, and review what’s been happening elsewhere in IP
Sukanya Sarkar shares her thoughts on this year’s annual meeting in Singapore, where debates ranged from AI opportunities to improving law firm culture
The court’s ruling is a good reminder that US parties aren’t guaranteed attorney fees just because they win, say sources
With business confidence in a shaky state, Rachel Tan and Lisa Yong of Rouse discuss how in-house IP teams can manage their trademark portfolios through uncertain times
The Court of Appeal had stern words for Med-El’s representatives after they highlighted a deputy judge’s background as a solicitor
Funders and NPEs say asserting patent portfolios can minimise risk at the USPTO’s PTAB, where procedure remains a controversial topic
The US Supreme Court’s ruling wasn’t a surprise and reflects a trend that had already been bubbling away for a while, say tech and pharma counsel